Literature DB >> 10415805

MMP inhibition by chemically modified tetracycline-3 (CMT-3) in equine pulmonary epithelial lining fluid.

P Maisi1, M Kiili, S M Raulo, E Pirilä, T Sorsa.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10415805     DOI: 10.1111/j.1749-6632.1999.tb07759.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  5 in total

1.  Effects of chemically modified tetracyclines (CMTs) in sensitive, multidrug resistant and apoptosis resistant leukaemia cell lines.

Authors:  M Tolomeo; S Grimaudo; S Milano; M La Rosa; V Ferlazzo; G Di Bella; C Barbera; D Simoni; P D'Agostino; E Cillari
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Alteration of the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, due to acute gastrointestinal toxicity of doxorubicin.

Authors:  Jing Li; Shufeng Zhou; Hung Huynh; Wei Duan; Eli Chan
Journal:  Pharm Res       Date:  2005-08-13       Impact factor: 4.200

3.  Significant intestinal excretion, one source of variability in pharmacokinetics of COL-3, a chemically modified tetracycline.

Authors:  Jing Li; Shufeng Zhou; Hung Huynh; Eli Chan
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

Review 4.  Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.

Authors:  P Zarogoulidis; N Papanas; I Kioumis; E Chatzaki; E Maltezos; K Zarogoulidis
Journal:  Eur J Clin Pharmacol       Date:  2011-11-22       Impact factor: 2.953

5.  Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications.

Authors:  Jose Garrido-Mesa; Kate Adams; Julio Galvez; Natividad Garrido-Mesa
Journal:  Expert Opin Investig Drugs       Date:  2022-03-23       Impact factor: 6.498

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.